CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $5.77.

A number of research firms have commented on CTMX. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th. StockNews.com cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th.

Institutional Investors Weigh In On CytomX Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in CytomX Therapeutics in the first quarter valued at $57,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of CytomX Therapeutics during the first quarter valued at about $124,000. XTX Topco Ltd raised its stake in shares of CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 48,033 shares in the last quarter. Forefront Analytics LLC raised its stake in shares of CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $1.15 on Friday. The company has a market cap of $89.61 million, a PE ratio of 5.75 and a beta of 1.04. The company has a fifty day moving average price of $1.21 and a two-hundred day moving average price of $1.64. CytomX Therapeutics has a 12 month low of $1.04 and a 12 month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $25.12 million during the quarter, compared to analyst estimates of $21.79 million. CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. During the same period in the prior year, the firm earned ($0.02) EPS. Equities research analysts anticipate that CytomX Therapeutics will post -0.2 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.